NOVARTIS logo.jpg
Novartis Kymriah® receives FDA Regenerative Medicine Advanced Therapy designation in follicular lymphoma
April 22, 2020 01:15 ET | Novartis International AG
If approved, relapsed or refractory (r/r) follicular lymphoma would become the third B-cell malignancy indication for Kymriah, joining approvals in children and young adults with r/r ALL, and adults...
NOVARTIS logo.jpg
AveXis receives positive CHMP opinion for Zolgensma®, the only gene therapy for spinal muscular atrophy (SMA)
March 27, 2020 08:59 ET | Novartis International AG
Zolgensma® (onasemnogene abeparvovec), a one-time administered gene therapy, has been recommended for European Commission (EC) conditional approval for patients with spinal muscular atrophy (SMA) and...
NOVARTIS logo.jpg
Zolgensma® data shows rapid, significant, clinically meaningful benefit in SMA including prolonged event-free survival, motor milestone achievement and durability now up to 5 years post-dosing
March 24, 2020 02:15 ET | Novartis International AG
Interim SPR1NT data showed presymptomatic babies with SMA treated with Zolgensma® (onasemnogene abeparvovec-xioi) soon after birth achieved age-appropriate motor milestones In addition to meeting both...
NOVARTIS logo.jpg
AveXis presents AVXS-101 IT data demonstrating remarkable increases in HFMSE scores and a consistent clinically meaningful response in older patients with SMA Type 2
March 24, 2020 02:13 ET | Novartis International AG
SMA Type 2 patients between two and five years of age who received Dose B met the primary efficacy endpoint with a remarkable mean increase of 6.0 points in HFMSE scores from baseline to month 12,...
NOVARTIS logo.jpg
Novartis receives approval from Japanese Ministry of Health, Labour and Welfare for Zolgensma® the only gene therapy for patients with spinal muscular atrophy (SMA)
March 19, 2020 02:15 ET | Novartis International AG
Zolgensma® (onasemnogene abeparvovec), a one-time administered gene therapy, is approved for the treatment of SMA in patients under the age of two, including those who are pre-symptomatic at...
Malia Lewin Joins CherryCircle Software as Chief Business Officer
March 11, 2020 08:00 ET | CherryCircle Software, Inc.
AUSTIN, Texas, March 11, 2020 (GLOBE NEWSWIRE) -- CherryCircle Software, Inc. announced today that Malia Lewin has joined its executive management team as Chief Business Officer. CherryCircle has...
NOVARTIS logo.jpg
Novartis Kymriah® demonstrates consistent efficacy and safety outcomes in US patients when used in real-world setting
December 09, 2019 14:45 ET | Novartis International AG
Efficacy in DLBCL confirmed results seen in the pivotal trial despite treatment of a broader population, including older and more heavily pretreated patients1-3  Fewer known CAR-T cell therapy adverse...